Preview

Артериальная гипертензия

Расширенный поиск

Повышенная частота сердечных сокращений у пациентов с артериальной гипертонией и ишемической болезнью сердца: маркер тяжести заболевания или корригируемый фактор риска при сохраненной фракции выброса левого желудочка

https://doi.org/10.18705/1607-419X-2019-25-4-389-406

Аннотация

Многочисленные исследования демонстрируют негативное прогностическое значение тахикардии, как в общей популяции, так и в отдельных подгруппах больных, в том числе имеющих ишемическую болезнь сердца (ИБС), артериальную гипертензию (АГ) и хроническую сердечную недостаточность с со­храненной фракцией выброса (СНсФВ). В последней редакции Европейских рекомендаций по ведению больных АГ уровень частоты сердечных сокращений (ЧСС), превышающий 80 уд/мин, выделен как от­дельный независимый предиктор неблагоприятных исходов. Однако эффективность фармакологического урежения ЧСС при синусовом ритме не определена, и поэтому возможность назначения пульсурежаю­щих препаратов следует рассматривать на любом этапе лечения АГ, если немедикаментозные методы коррекции ЧСС с доказанным влиянием на прогноз оказались недостаточными. В отличие от пациентов со сниженной фракцией выброса (ФВ) левого желудочка (ЛЖ), у которых прослежены положительные эффекты пульсурежающей терапии, данные о влиянии медикаментозного снижения ЧСС на прогноз больных АГ, ИБС и/или СНсФВ не столь однозначны. При этом обсуждаются и некоторые неблагопри­ятные последствия фармакологической коррекции ЧСС у таких пациентов, которые могут быть следстви­ем изменения контура давления в аорте с его повышением в позднюю систолу в условиях имеющейся диастолической дисфункции ЛЖ. В обзоре представлены данные, отражающие многообразие проблемы клинико-прогностической значимости повышенной ЧСС и ее коррекции у пациентов с АГ, стабильной ИБС и/или СНсФВ.

Об авторах

Е. В. Кохан
Федеральное государственное автономное образовательное учреждение высшего образования «Российский университет дружбы народов»
Россия

Кохан Елизавета Васильевна — клинический ординатор кафедры внутренних болезней с курсом кардиологии и функ­циональной диагностики имени академика В. С. Моисеева

ул. Вавилова, д. 61, Москва,  117292

SPIN-код: 1307-6750



Г. К. Киякбаев
Федеральное государственное автономное образовательное учреждение высшего образования «Российский университет дружбы народов»
Россия

Киякбаев Гайрат Калуевич — доктор медицинских наук, профессор, профессор кафедры внутренних болезней с курсом кардиологии и функциональной диагностики имени академика В. С. Моисеева

Москва

SPIN-код: 3192-2303



Ж. Д. Кобалава
Федеральное государственное автономное образовательное учреждение высшего образования «Российский университет дружбы народов»
Россия

Кобалава Жанна Давидовна — доктор медицинских на­ук, профессор, заведующая кафедрой внутренних болезней с курсом кардиологии и функциональной диагностики имени академика В. С. Моисеева

Москва

SPIN-код: 9828-5409



Список литературы

1. Kannel WB, Kannel C, Paffenbarger R, Cupples L. Heart rate and cardiovascular mortality: the Framingham Study. Am Heart J. 1987;113(6):1489–1494. doi:10.1016/0002-8703(87)90666-1

2. Dyer A, Persky V, Stamler J, Paul O, Shekelle R, Berkson Det al. Heart rate as a prognostic factor for coronary heart disease and mortality: findings in three Chicago epidemiologic studies. Am J Epidemiol. 1980;112(6):736–749. doi:10.1093/oxfordjournals.aje.a113046

3. Yu J, Dai L, Zhao Q, Liu X, Chen S, Wang A et al. Association of cumulative exposure to resting heart rate with risk of stroke in general population: the Kailuan Cohort Study. J Stroke Cerebrovasc Dis. 2017;26(11):2501–2509. doi:10.1016/j.jstrokecerebrovasdis.2017.05.037

4. Castagno D, Skali H, Takeuchi M, Swedberg K, Yusuf S, Granger C et al. Association of heart rate and outcomes in a broad spectrum of patients with chronic heart failure. J Am Coll Cardiol. 2012;59(20):1785–1795. doi:10.1016/j.jacc.2011.12.044

5. Hillis G, Woodward M, Rodgers A, Chow C, Li Q, Zoungas Set al. Resting heart rate and the risk of death and cardiovascular complications in patients with type 2 diabetes mellitus. Diabetologia. 2012;55(5):1283–1290. doi:10.1007/s00125-012-2471-y

6. Gillman M, Kannel W, Belanger A, D’Agostino R. Influence of heart rate on mortality among persons with hypertension: the Framingham Study. Am Heart J. 1993;125(4):1148–1154. doi:10.1016/0002-8703(93)90128-V

7. Kannel W, Wilson P, Blair S. Epidemiological assessment of the role of physical activity and fitness in development of cardiovascular disease. Am Heart J. 1985;109(4):876–885. doi:10.1016/0002-8703(85)90653–2

8. Seals D, Chase P. Influence of physical training on heart rate variability and baroreflex circulatory control. J Appl Physiol. 1989;66(4):1886–1895. doi:10.1152/jappl.1989.66.4.1886

9. Kjekshus J, Gullestad L. Heart rate as a therapeutic target in heart failure. Eur Heart J. 1999;1:64–69.

10. Fácila L, Pallarés V, Peset A, Perez A, Gil V, Montagud V et al. Twenty-four-hour ambulatory heart rate and organ damage in primary hypertension. Blood Press. 2010;19(2):104–109. doi:10.3109/08037050903525103

11. Böhm M, Reil JC, Danchin N, Thoenes M, Bramlage P,Volpe M. Association of heart rate with microalbuminuria in cardiovascular risk patients: data from I SEARCH. J Hypertens. 2008;26(1):18–25. doi:10.1097/HJH.0b013e3282f05c8a

12. Benetos A, Adamopoulos C, Bureau J, Temmar M, Labat C,Bean K et al. Determinants of accelerated progression of arterial stiffness in normotensive subjects and in treated hypertensive subjects over a 6 year period. Circulation. 2002;105(10):1202–1207.doi:10.1161/hc1002.105135

13. Paul L, Hastie C, Li W, Harrow C, Muir S, Connell J et al.Resting heart rate pattern during follow-up and mortality in hypertensive patients. Hypertension. 2010;55(2):567–574. doi:10.1161/HYPERTENSIONAHA.109.144808

14. Okin P, Kjeldsen S, Julius S, Hille D, Dahlof B, Edelman Jet al. All-cause and cardiovascular mortality in relation to changing heart rate during treatment of hypertensive patients with electrocardiographic left ventricular hypertrophy. Eur Heart J. 2010;31(18):2271–2279. doi:10.1093/eurheartj/ehq225

15. Julius S, Palatini P, Kjeldsen S, Zanchetti A, Weber M, Mcinnes G et al. Usefulness of heart rate to predict cardiac events in treated patients with high-risk systemic hypertension. Am J Cardiol. 2012;109(5):685–692. doi:10.1016/j.amjcard.2011.10.025

16. Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M et al. 2018 ESC/ESH Guidelines for the mana-gement of arterial hypertension. Eur Heart J. 2018;39(33):3021–3104. doi:10.1093/eurheartj/ehy339

17. Кобалава Ж. Д., Конради А. О., Недогода С. В., Арутюнов Г. П., Баранова Е. И., Барбараш О. Л. и др. Меморандум экспертов Российского кардиологического общества по рекомендациям Европейского общества кардиологов / Европейского общества по артериальной гипертензии по лечению артериальной гипертензии 2018 года. Российский кардиоло¬гический журнал. 2018;(12):131–142. doi:10.15829/1560-4071-2018-12-131-142

18. Farinaro E, Stranges S, Guglielmucci G, Iermano P,Celentano E, Cajafa A et al. Heart rate as a risk factor in hypertensive individuals. The Italian TensioPulse Study. Nutr Metab Cardiovasc Dis. 1999;9(4):196–202.

19. Palatini P, Dorigatti F, Zaetta V, Mormino P, Mazzer A, Bortolazzi A et al. Heart rate as a predictor of development of sustained hypertension in subjects screened for stage 1 hypertension: the HARVEST Study. J Hypertens. 2006;24(9):1873–1880. doi:10.1097/01.hjh.0000242413.96277.5b

20. Карпов Ю. А., Чазова И. Е., Вигдорчик А. В. От лица исследовательской группы. Эффективность и безопасность комбинации амлодипина и валсартана в лечении артериальной гипертонии в условиях реальной клинической практики: результаты российского наблюдательного исследования ЭКСТРА 2. Системные гипертензии. 2010;4:14–20.

21. Кобалава Ж. Д., Котовская Ю. В., Лукьянова Е. А. Ком¬бинированная терапия артериальной гипертонии с исполь зованием фиксированной комбинации периндоприла аргинина/амлодипина в реальной клинической практике: организация и основные результаты программы КОНСТАНТА.Кардиология. 2013;53(6):25–34.

22. King D, Everett C, Mainous A, Liszka H. Long-retm prog-nostic value of resting heart rate in subjects with prehypertension. Am J Hypertens. 2006;19(8):796–800. doi:10.1016/j.amjhyper.2006.01.019

23. Salles G, Cardoso C, Fonseca L, Fiszman R, Muxfeldt E.Prognostic significance of baseline heart rate and its interaction with beta-blocker use in resistant hypertension: a Cohort Study.Am J Hypertens. 2013;26(2):218–226. doi:10.1093/ajh/hps004

24. Kolloch R, Legler U, Champion A, Cooper-Dehoff R, Handberg E, Zhou Q et al. Impact of resting heart rate on outcomes in hypertensive patients with coronary artery disease: findings from the INternational VErapamil-SR/trandolapril STudy (INVEST). Eur Heart J. 2007;29(10):1327–1334. doi:10.1093/eurheartj/ehn123

25. Montalescot G, Sechtem U, Achenbach S, Andreotti F, Arden C, Budaj A et al. 2013 ESC guidelines on the management of stable coronary artery disease. Eur Heart J. 2013;34(38):2949–3003. doi:10.1093/eurheartj/eht296

26. Bangalore S, Wun C, Demicco D. Heart rate in patients with coronary artery disease — the lower the better? An analysis from the Treating to New Targets (TNT) trial (Abstr). Eur Heart J. 2011;32(Suppl.):339–346.

27. Diaz A, Bourassa M, Guertin M, Tardif J. Long-term prognostic value of resting heart rate in patients with suspected or proven coronary artery disease. Eur Heart J. 2005;26(10):967–974. doi:10.1093/eurheartj/ehi190

28. Anselmino M, Ohrvik J, Ryden L, Euro Heart SurveyInvestigators. Resting heart rate in patients with stable coronary artery disease and diabetes: a report from the Euro Heart Survey on Diabetes and the Heart. Eur Heart J. 2010;31(24):3040–3045. doi:10.1093/eurheartj/ehq368

29. Paterson A, Rutledge B, Cleary P, Lachin J, Crow R, DiabetesControl and Complications Trial/Epidemiology of DiabetesInterventions and Complications Research Group. The effect of intensive diabetes treatment on resting heart rate in type 1 diabetes: the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study. Diabetes Care. 2007;30(8):2107–2112. doi:10.2337/dc06–1441

30. Julius S, Palatini P, Kjeldsen S, Zanchetti A, Weber M, McInnes G et al. Tachycardia predicts cardiovascular events in the VALUE trial. Am Soc Hypertension. 2010 Scientific Meeting. 2010. New York. NY. Abstract LB-OR 01.

31. Lonn E, Rambihar S, Gao P, Custodis F, Sliwa K, Teo Ket al. Heart rate is associated with increased risk of major cardiovascular events, cardiovascular and all-cause death in patients with stable chronic cardiovascular disease: an analysis of ONTARGET/TRANSCEND. Clin Res Cardiol. 2014;103(2):149–159. doi:10.1007/s00392-013-0644-4

32. Poulter NR, Dobson JE, Sever PS, Dahlof B, Wedel H,Camobell N; ASCOT Investigators. Baseline heart rate, antihyper-tensive treatment, and prevention of cardiovascular outcomesin ASCOT (Anglo-Scandinavian Cardiac Outcomes Trial). J Am CollCardiol. 2009;54(13):1154–1161. doi:10.1016/j.jacc.2009.04.087

33. Palatini P. Elevated heart rate in hypertension: a target for treatment? J Am Coll Cardiol. 2010;55(9):931–932. doi:10.1016/j.jacc.2009.10.034

34. Palatini P. Is there benefit of cardiac slowing drugs in the treatment of hypertensive patients with elevated heart rate? Eur Heart J. 2008;29(10):1218–1220. doi:10.1093/eurheartj/ehn164

35. McAlister F, Wiebe N, Ezekowitz J, Leung A, Armstrong P.Meta-analysis: beta-blocker dose, heart rate reduction, and death in patients with heart failure. Ann Intern Med. 2009;150(11):784–794. doi:10.7326/0003-4819-150-11-200906020-00006

36. Cullington D, Goode K, Zhang J, Cleland J, Clark A. Is heart rate important for patients with heart failure in atrial fibrillation? JACC Hear Fail. 2014;2(3):213–220. doi:10.1016/j.jchf.2014.01.005

37. Lee D, Gona P, Vasan R, Larson M, Benjamin E, Wang T et al. Relation of disease pathogenesis and risk factors to heart failure with preserved or reduced ejection fraction. Circulation. 2009;119(24):3070–3077. doi:10.1161/CIRCULATIONAHA.108.815944

38. O’Neal W, Sandesara P, Samman-Tahhan A, Kelli H,Hammadah M, Soliman E. Heart rate and the risk of adverse outcomes in patients with heart failure with preserved ejection fraction. Eur J Prev Cardiol. 2017;24(11):1212–1219. doi:10.1177/2047487317708676

39. Takada T, Sakata Y, Miyata S, Takahashi J, Nochioka K, Miura M et al. Impact of elevated heart rate on clinical outcomes in patients with heart failure with reduced and preserved ejection fraction: a report from the CHART 2 Study. Eur J Heart Fail. 2014;16(3):309–316. doi:10.1002/ejhf.22

40. Castagno D, Skali H, Takeuchi M, Swedberg K, Yusuf S, Granger C et al. Association of heart rate and outcomes in a broad spectrum of patients with chronic heart failure. J Am Coll Cardiol. 2012;59(20):1785–1795. doi:10.1016/j.jacc.2011.12.044

41. Böhm M, Perez A, Jhund P, Reil J, Komajda M, Zile M et al. Relationship between heart rate and mortality and morbidity in the irbesartan patients with heart failure and preserved systolic function trial (I Preserve). Eur J Heart Fail. 2014;16(7):778–787. doi:10.1002/ejhf.85.

42. Maeder M, Kaye D. Differential impact of heart rate and blood pressure on outcome in patients with heart failure with reduced versus preserved left ventricular ejection fraction. Int J Cardiol. 2012;155(2):249–256. doi:10.1016/j.ijcard.2010.10.007

43. Vazir A, Claggett B, Pitt B, Anand I, Sweitzer N, Fang J et al. Prognostic importance of temporal changes in resting heart rate in heart failure and preserved ejection fraction. JACC Hear Fail. 2017;5(11):782–791. doi:10.1016/j.jchf.2017.08.018

44. Robinson B, Epstein S, Beiser G, Braunwald E. Control of heart rate by the autonomic nervous system. Studies in man on the interrelation between baroreceptor mechanisms and exercise. Circ Res. 1966;19(2):400–411. doi:10.1161/01.RES.19.2.400

45. Kobalava Z, Khomitsakaya Y, Kiyakbaev G; ATHENA trial investigators. Achievement of target heart rate on beta-blockers in patients with stable angina and hypertension (ATHENA) in routine clinical practice in Russia. Curr Med Res Opin. 2014;30 (5):805–811. doi:10.1185/03007995.2013.874993

46. Zhang S, Wu J, Zhou J, Liang Z, Qiu Q, Xu T et al. Overweight, resting heart rate, and prediabetes/diabetes: a population-based prospective cohort study among Inner Mongolians in China. Sci Rep. 2016;6:23939. doi:10.1038/srep23939

47. Wang C, Li Y, Li L, Wang L, Zhao J, You A et al. Relationshipbetween resting pulse rate and lipid metabolic dysfunctions in Chinese adults living in rural areas. PLoS One. 2012;7(11): e49347. doi:10.1371/journal.pone.0049347

48. Sun J, Huang X, Deng X, Lv X, Lu J, Chen Y et al. Elevated resting heart rate is associated with dyslipidemia in middle-aged and elderly Chinese. Biomed Environ Sci. 2014;27(8):601–605. doi:10.3967/bes2014.092

49. Shigetoh Y, Adachi H, Yamagishi S, Enomoto M, Fukami A, Otsuka M et al. Higher heart rate may predispose to obesity and diabetes mellitus: 20 year Prospective Study in a General Population. Am J Hypertens. 2009;22(2):151–155. doi:10.1038/ajh.2008.331

50. Egan B. Insulin resistance and the sympathetic nervous system. Curr Hypertens Rep. 2003;5(3):247–254. doi:10.1007/s11906-003-0028-7

51. Carnethon M, Yan L, Greenland P, Garside D, Dyer A, Metzger B et al. Resting heart rate in middle age and diabetes development in older age. Diabetes Care. 2008;31(2):335–339. doi:10.2337/dc07-0874

52. Sharma K, Kass D. Heart failure with preserved ejection fraction. Circ Res. 2014;115(1):79–96. doi:10.1161/CIRCRESAHA.115.302922

53. Samson R, Jaiswal A, Ennezat P, Cassidy M, Le Jemtel T.Clinical phenotypes in heart failure with preserved ejection fraction. J Am Heart Assoc. 2016;5(1): e002477. doi:10.1161/JAHA.115.002477

54. Obokata M, Reddy Y, Pislaru S, Melenovsky V, Borlaug B. Evidence supporting the existence of a distinct obese phenotype of heart failure with preserved ejection fraction. Circulation. 2017;136(1):6–19. doi:10.1161/CIRCULATIONAHA.116.026807

55. Кобалава Ж. Д., Шаварова Е. К. Частота сердечных сокращений у больных артериальной гипертонией: возможный маркер повышенного риска или самостоятельная терапевтическая мишень? Системные гипертензии. 2015;12(2):13–18.

56. Ho J, Lyass A, Lee D, Vasan S, Kannel W, Larson G et al.Predictors of new-onset heart failure. Circ Hear Fail. 2013;6 (2):279–286. doi:10.1161/CIRCHEARTFAILURE.112.972828

57. Perski A, Olsson G, Landou C, de Faire U, Theorell T, Hamsten A. Minimum heart rate and coronary atherosclerosis: independent relations to global severity and rate of progression of angiographic lesions in men with myocardial infarction at a young age. Am Heart J. 1992;123(3):609–616. doi:10.1016/0002-8703(92)90497-J

58. Perski A, Hamsten A, Lindvall K, Theorell T. Heart rate correlates with severity of coronary atherosclerosis in young postinfarction patients. Am Heart J. 1988;116(5Pt1):1369–1373. doi:10.1016/0002-8703(88)90469-3

59. Heidland U, Strauer B. Left ventricular muscle mass andelevated heart rate are associated with coronary plaque disruption.Circulation. 2001;104(13):1477–1482. doi:10.1161/hc3801.096325

60. Heusch G. Heart rate in the pathophysiology of coronary blood flow and myocardial ischaemia: benefit from selective bradycardic agents. Br J Pharmacol. 2008;153(8):1589–1601. doi:10.1038/sj.bjp.0707673

61. Chow B, Rabkin S. The relationship between arterial stiffness and heart failure with preserved ejection fraction: a systemic meta-analysis. Heart Fail Rev. 2015;20(3):291–303. doi:10.1007/s10741-015-9471-1

62. Zito C, Mohammed M, Todaro M, Khandheria B, Cusma-Piccione M, Oreto G et al. Interplay between arterial stiffness and diastolic function. J Cardiovasc Med. 2014;15(11):788–796. doi:10.2459/JCM.0000000000000093

63. Park K, Kim H, Oh S, Lim W, Seo J, Chung W et al. Asso-ciation between reduced arterial stiffness and preserved diastolic function of the left ventricle in middle-aged and elderly patients. J Clin Hypertens. 2017;19(6):620–626. doi:10.1111/jch.12968

64. Namba T, Masaki N, Matsuo Y, Sato A, Kimura T, Horii S et al. Arterial stiffness is significantly associated with left ventricular diastolic dysfunction in patients with cardiovascular disease. Int Heart J. 2016;57(6):729–735. doi:10.1536/ihj.16-112

65. Hu Y, Li L, Shen L, Gao H. The relationship between arterial wall stiffness and left ventricular dysfunction. Netherlands Heart J. 2013;21(5):222–227. doi:10.1007/s12471-012-0353-z

66. Pandey A, Khan H, Newman A, Lakatta E, Forman D, Butler J et al. Arterial stiffness and risk of overall heart failure, heart failure with preserved ejection fraction and heart failure with reduced ejection fraction. Hypertension. 2017;69(2):267–274. doi:10.1161/HYPERTENSIONAHA.116.08327

67. Mangoni A, Mircoli L, Giannattasio C, Ferrari A, Mancia G.Heart rate-dependence of arterial distensibility in vivo. J Hypertens. 1996;14(7):897–901. doi: https://doi.org/10.1097/00004872-199607000-00013

68. Custodis F, Baumhäkel M, Schlimmer N, List F, Gensch C, Bohm M et al. Heart rate reduction by ivabradine reduces oxidative stress, improves endothelial function and prevents atherosclerosis in apolipoprotein e deficient mice. Circulation. 2008;117(18):2377–2387. doi:10.1161/CIRCULATIONAHA.107.746537

69. Tan I, Butlin M, Spronck B, Xiao H, Avolio A. Effect of heart rate on arterial stiffness as assessed by pulse wave velocity. Curr Hypertens Rev. 2017;13(2):107–122. doi:10.2174/1573402113666170724100418

70. Wilkinson I, Mohammad N, Tyrrell S, Hall I, Webb D, Paul V et al. Heart rate dependency of pulse pressure amplification and arterial stiffness. Am J Hypertens. 2002;15(1Pt1):24–30. doi:10.1016/s0895-7061(01)02252-x

71. Wilkinson I, MacCallum H, Flint L, Cockcroft J, Newby D,Webb D. The influence of heart rate on augmentation index and central arterial pressure in humans. J Physiol. 2000;525(Pt1):263–270. doi:10.1111/j.1469-7793.2000.t01-1-00263.x

72. Whelton S, Blankstein R, Al-Mallah M, Lima J, Bluemke D,Hundley W et al. Association of resting heart rate with carotid and aortic arterial stiffness. Hypertension. 2013;62(3):477–484. doi:10.1161/HYPERTENSIONAHA.113.01605

73. Xiao H, Tan I, Butlin M, Li D, Avolio AP. Mechanism underlying the heart rate dependency of wave reflection in the aorta: a numerical simulation. Am J Physiol Circ Physiol. 2018;314(3): H443-H451. doi:10.1152/ajpheart.00559.2017

74. Williams B, Lacy P, CAFE and the ASCOT (Anglo-Scandinavian Cardiac Outcomes Trial) Investigators. Impact of heart rate on central aortic pressures and hemodynamics. J Am Coll Cardiol. 2009;54(8):705–713. doi:10.1016/j.jacc.2009.02.088

75. Шаваров А. А., Киякбаев Г. К., Кобалава Ж. Д. Центральное давление и артериальная жесткость у больных стабильной стенокардией и артериальной гипертонией без систолической дисфункции левого желудочка: эффекты атенолола и ивабрадина. Сердечная недостаточность. 2015;16(3):179–186. doi:10.18087/rhfj.2015.3.2101

76. Protogerou A, Safar M. Dissociation between central augmentation index and carotid-femoral pulse-wave velocity: when and why? Am J Hypertens. 2007;20(6):648–649. doi:10.1016/j.amjhyper.2007.02.008

77. Fox K, Ford I, Steg P, Tardif J, Tendera M, Ferrari R.Ivabradine in stable coronary artery disease without clinical heart failure. N Engl J Med. 2014;371(12):1091–1099. doi:10.1056/NEJMoa1406430

78. Komajda M, Isnard R, Cohen-Solal A, Metra M, Pieske B,Ponikowski P et al. Effect of ivabradine in patients with heart failure with preserved ejection fraction: the EDIFY randomized placebo-controlled trial. Eur J Heart Fail. 2017;19(11):1495–1503. doi:10.1002/ejhf.876

79. Tardif J, Ford I, Tendera M, Bourassa M, Fox K, INITIATIVE Investigators. Efficacy of ivabradine, a new selectiveI(f) inhibitor, compared with atenolol in patients with chronic stable angina. Eur Heart J. 2005;26(23):2529–2536. doi:10.1093/eurheartj/ehi586

80. Pepine C, Handberg E, Cooper-DeHoff R, Marks R, Kowey P, Messerli F et al. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. J Am Med Assoc. 2003;290(21):2805. doi:10.1001/jama.290.21.2805

81. Cucherat M. Quantitative relationship between resting heart rate reduction and magnitude of clinical benefits in post-myocardial infarction: a meta-regression of randomized clinical trials. Eur Heart J. 2007;28(24):3012–3019. doi:10.1093/eurheartj/ehm489.

82. Dondo T, Hall M, West R, Jernberg T, Lindahl B, Bueno H et al. β-blockers and mortality after acute myocardial infarction in patients without heart failure or ventricular dysfunction. J Am Coll Cardiol. 2017;69(22):2710–2720. doi:10.1016/j.jacc.2017.03.578

83. Abbasi J. Do all patients need β-blockers after a heart attack? J Am Med Assoc. 2018;319(9):853. doi:10.1001/jama.2018.0107

84. Bangalore S, Makani H, Radford M, Thakur K, Toklu B, Katz S et al. Clinical outcomes with β-blockers for myocar-dial infarction: a meta-analysis of randomized trials. Am J Med.2014;127(10):939–953. doi:10.1016/j.amjmed.2014.05.032

85. Sorbets E, Steg P, Young R, Danchin N, Greenlaw N, Ford I et al. β-blockers, calcium antagonists, and mortality in stable coronary artery disease: an international cohort study. Eur Heart J. 2019;40(18):1399–1407. doi:10.1093/eurheartj/ehy811

86. [Electronic resource] BEtablocker Treatment After AcuteMyocardial Infarction in patients without reduced left ventricularsystolic function (BETAMI) (NCT03646357). URL: https://clinicaltrials.gov/ct2/show/NCT03646357.

87. [Electronic resource] Evaluation of decreased usage of betablockers after myocardial infarction in the SWEDEHEART Registry (REDUCE-SWEDEHEART) (NCT 03278509). URL: https://clinicaltrials.gov/ct2/show/NCT03278509.

88. [Electronic resource] TREatment With Beta-blockers After myOcardial Infarction wothOut Reduced Ejection fracTion(NCT03596385). URL: https://clinicaltrials.gov/ct2/show/NCT03596385.

89. [Electronic resource] Beta blocker interruption after uncomplicated myocardial infarction (A βYSS) (NCT03498066). URL: https://clinicaltrials.gov/ct2/show/NCT03498066.

90. Flather M, Shibata M, Coats A, Van Veldhuisen D, Parkhomenko A, Borbola J et al. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J. 2005;26(3):215–225. doi:10.1093/eurheartj/ehi115

91. Yamamoto K, Origasa H, Hori M, J DHF Investigators. Effects of carvedilol on heart failure with preserved ejection fraction: the Japanese Diastolic Heart Failure Study (J DHF). Eur J Heart Fail. 2013;15(1):110–118. doi:10.1093/eurjhf/hfs141

92. Conraads V, Metra M, Kamp O, De Keulenaer G, Pieske B,Zamorano J et al. Effects of the long-term administration of nebivolol on the clinical symptoms, exercise capacity, and left ventricular function of patients with diastolic dysfunction: results of the ELANDD study. Eur J Heart Fail. 2012;14(2):219–225. doi:10.1093/eurjhf/hfr161

93. Cleland J, Bunting K, Flather M, Altman D, Holmes J, Coats A et al. Beta-blockers for heart failure with reduced, mid-range, and preserved ejection fraction: an individual patient-level analysis of double-blind randomized trials. Eur Heart J. 2018;39 (1):26–35. doi:10.1093/eurheartj/ehx564

94. Dahlöf B, Devereux R, Kjeldsen S, Julius S, Beevers G, de Faire U et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002;359 (9311):995–1003. doi:10.1016/S0140-6736(02)08089-3

95. Dahlöf B, Sever P, Poulter N, Wedel H, Beevers D, Caulfield M et al. Prevention of cardiovascular events with an antihyper-tensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet. 2005;366(9489):895–906. doi:10.1016/S0140-6736(05)67185-1

96. Poulter N, Dobson J, Sever P, Dahlof B, Wedel H, Campbell N. Baseline heart rate, antihypertensive treatment and prevention of cardiovascular outcomes in ASCOT (Anglo-Scandinavian Cardiac Outcomes Trial). J Am Coll Cardiol. 2009;54 (13):1154–1161. doi:10.1016/j.jacc.2009.04.087

97. Bangalore S, Sawhney S, Messerli F. Relation of beta-blocker-induced heart rate lowering and cardioprotection in hypertension. J Am Coll Cardiol. 2008;52(18):1482–1489. doi:10.1016/j.jacc.2008.06.048

98. [Electronic resource] Hypertension in adults: diagnosis and management guidance and guidelines. NICE. URL: https://www.nice.org.uk/guidance/cg127.2018.

99. Whelton P, Carey R, Aronow W, Casey D, Collins K,Dennison Himmelfarb C et al. 2017 ACC/AHA/AAPA/ABC/ACPM/ AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the prevention, detection, evaluation and management of high blood pressure in adults: a Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertens. (Dallas, Tex. 1979). 2017;68 (3):543–589. doi:10.1016/j.jash.2018.06.010

100. Palatini P, Rosei E, Casiglia E, Chalmers J, Ferrari R, Grassi G et al. Management of the hypertensive patient with elevated heart rate: Statement of the Second Consensus Conference endorsed by the European Society of Hypertension. J Hypertens. 2016;34 (5):813–821. doi:10.1097/HJH.0000000000000865

101. Cody R. The sympathetic nervous system and the renin-angiotensin-aldosterone system in cardiovascular disease. Am J Cardiol. 1997;80(9B):9J–14J. doi:10.1016/S0002-9149(97)00832-1

102. Chern C, Hsu H, Hu H, Chen Y, Hsu L, Chao A. Effects of atenolol and losartan on baroreflex sensitivity and heart ratevariability in uncomplicated essential hypertension. J Cardiovasc Pharmacol. 2006;47 (2):169–174. doi:10.1097/01.fjc.0000199225.17928.f5

103. La Rovere M, Bigger J, Marcus F, Mortara A, Schwartz P.Baroreflex sensitivity and heart-rate variability in prediction of total cardiac mortality after myocardial infarction. ATRAMI (Autonomic Tone and Reflexes After Myocardial Infarction) Investigators. Lancet (London, England). 1998;351(9101):478–484. doi:10.1016/S0140-6736(97)11144-8

104. Hillebrand S, Gast K, de Mutsert R, Swenne C, Jukema J,Middeldorp S et al. Heart rate variability and first cardiovascular event in populations without known cardiovascular disease: meta-analysis and dose–response meta-regression. EP Eur. 2013;15 (5):742–749. doi:10.1093/europace/eus341

105. May O, Arildsen H. Long-term predictive power of heart rate variability on all-cause mortality in the diabetic population. Acta Diabetol. 2011;48(1):55–59. doi:10.1007/s00592-010-0222-4

106. Nolan J, Batin P, Andrews R, Lindsay S, Brooksby P, Mullen M et al. Prospective study of heart rate variability and mortality in chronic heart failure. Circulation. 1998;98(15):1510–1516. doi:10.1161/01.CIR.98.15.1510

107. Tsuji H, Venditti F, Manders E, Evans J, Larson M, Feldman C et al. Reduced heart rate variability and mortality risk in an elderly cohort. The Framingham Heart Study. Circulation. 1994;90(2):878–883. doi:10.1161/01.CIR.90.2.878

108. Ligtenberg G, Blankestijn P, Oey P, Klein I, Dijkhorst-Oei L, Boomsma G et al. Reduction of sympathetic hyperactivity by enalapril in patients with chronic renal failure. N Engl J Med. 1999;340(17):1321–1328. doi:10.1056/NEJM199904293401704

109. Sakata K, Shirotani M, Yoshida H, Kurata C. Comparison of effects of enalapril and nitrendipine on cardiac sympathetic nervous system in essential hypertension. J Am Coll Cardiol. 1998;32(2):438–443. doi:10.1016/S0735-1097(98)00261-7

110. Materson B, Reda D, Williams D. Comparison of effectsof antihypertensive drugs on heart rate: changes from baseline bybaseline group and over time. Department of Veterans Affairs Coope-rative Study Group on Antihypertensive Agents. Am J Hypertens. 1998;11(5):597–601. doi:10.1016/S0895-7061(97)00495-0

111. Pierdomenico S, Bucci A, Lapenna D, Cuccurullo F,Mezzetti A. Heart rate in hypertensive patients treated with ACEinhibitors and long-acting dihydropyridine calcium antagonists. J Cardiovasc Pharmacol. 2002;40(2):288–295. doi:10.1097/01.FJC.0000018374.52957.8F

112. Dart A, Reid C, McGrath B, Tonometry Study Group. Effects of ACE inhibitor therapy on derived central arterial waveforms in hypertension. Am J Hypertens. 2001;14(8 Pt 1):804–810. doi:10.1016/s0895-7061(01)02142-2

113. Morgan T, Lauri J, Bertram D, Anderson A. Effect of different antihypertensive drug classes on central aortic pressure.Am J Hypertens. 2004;17(2):118–123. doi:10.1016/j.amjhyper.2003.09.012

114. Van Gelder I, Groenveld H, Crijns H, Tuininga Y, Tijssen J,Alings A et al. Lenient versus strict rate control in patients with atrial fibrillation. N Engl J Med. 2010;362(15):1363–1373. doi:10.1056/NEJMoa1001337

115. Kotecha D, Holmes J, Krum H, Altman D, Manzano L, Cleland J et al. Efficacy of β-blockers in patients with heart failure plus atrial fibrillation: an individual-patient data meta-analysis. Lancet. 2014;384(9961):2235–2243. doi:10.1016/S0140-6736(14)61373-8

116. Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016;37(38):2893–2962. doi:10.1093/eurheartj/ehw210

117. Vlachopoulos C, Aznaouridis K, O’Rourke M, Safar M, Baou K, Stefanadis C. Prediction of cardiovascular events and all-cause mortality with central haemodynamics: a systematic review and meta-analysis. Eur Heart J. 2010;31(15):1865–1871. doi:10.1093/eurheartj/ehq024

118. Wilkinson I, Mohammad N, Tyrrell S, Hall I, Webb D, Paul V et al. Heart rate dependency of pulse pressure amplification and arterial stiffness. Am J Hypertens. 2002;15(1):24–30. doi:10.1016/s0895-7061(01)02252-x

119. Wilkinson I, MacCallum H, Flint L, Cockcroft J, Newby D,Webb D. The influence of heart rate on augmentation index and central arterial pressure in humans. J Physiol. 2000;525(Pt 1):263–270. doi:10.1111/j.1469-7793.2000.t01-1-00263.x

120. Nichols W, Edwards D. Arterial elastance and wave reflection augmentation of systolic blood pressure: deleterious effects and implications for therapy. J Cardiovasc Pharmacol Ther. 2001;6(1):5–21. doi:10.1177/107424840100600102

121. Williams B, Lacy P, CAFE and the ASCOT (Anglo-Scandinavian Cardiac Outcomes Trial) Investigators. Impact of heart rate on central aortic pressures and hemodynamics. J Am Coll Cardiol. 2009;54(8):705–713. doi:10.1016/j.jacc.2009.02.088

122. Messerli F, Rimoldi S, Bangalore S, Bavishi C, Laurent S.When an Increase in Central systolic pressure overrides the benefits of heart rate lowering. J Am Coll Cardiol. 2016;68(7):754–762. doi:10.1016/j.jacc.2016.03.610

123. Goupil R, Dupuis D, Troyanov S, Madore F, Agharazii M.Heart rate dependent and independent effects of beta-blockers on central hemodynamic parameters. J Hypertens. 2016;34(8):1535–1543. doi:10.1097/HJH.0000000000000978

124. Rimoldi S, Messerli F, Cerny D, Gloekler S, Traupe T,Laurent S et al. Selective heart rate reduction with ivabradineincreases central blood pressure in stable coronary artery disease.Hypertension. 2016;67(6):1205–1210. doi:10.1161/HYPERTEN-SIONAHA.116.07250

125. Tanna M, Messerli F, Bangalore S. Stable coronaryartery disease: are there therapeutic benefits of heart rate lowering? J Hypertens. 2019;37(6):1112–1118. doi:10.1097/HJH.0000000000002041

126. Zhao L, Song Y, Dong P, Li Z, Yang X, Wang S. Brachial pulse pressure and cardiovascular or all-cause mortality in the general population: a meta-analysis of Prospective Observational Studies.J Clin Hypertens. 2014;16(9):678–685. doi:10.1111/jch.12375

127. London G, Asmar R, O’Rourke M, Safar M, REASON Project Investigators. Mechanism(s) of selective systolic bloodpressure reduction after a low-dose combination of perindopril/indapamide in hypertensive subjects: comparison with atenolol. J Am Coll Cardiol. 2004;43(1):92–99. doi:10.1016/j.jacc.2003.07.039

128. Boutouyrie P, Achouba A, Trunet P, Laurent S, EXPLOR Trialist Group. Amlodipine-valsartan combination decreases central systolic blood pressure more effectively than the amlodipine-atenolol combination. Hypertension. 2010;55(6):1314–1322. doi:10.1161/HYPERTENSIONAHA.109.148999

129. Melenovsky V, Hwang S, Redfield M, Zakeri R, Lin G, Borlaug B. Left atrial remodeling and function in advanced heartfailure with preserved or reduced ejection fraction. Circ Hear Fail. 2015;8(2):295–303. doi:10.1161/CIRCHEARTFAILURE.114.001667

130. Zhou W, Wang R, Li Y, Chen D, Chen E, Zhu D et al. A ran-domized controlled study on the effects of bisoprolol and atenolol on sympathetic nervous activity and central aortic pressure in patients with essential hypertension. PLoS One. 2013;8(9):e72102. doi:10.1371/journal.pone.0072102

131. Кобалава Ж. Д., Котовская Ю. В., Богомаз А. В. Фиксированная комбинация бисопролола и амлодипина нивелирует влияние β-адреноблокатора на показатели центральной пульсовой волны у больных артериальной гипертонией. Кардиология. 2015;55(12):11–16.

132. Agabiti-Rosei E, Porteri E, Rizzoni D. Arterial stiffness, hypertension and rational use of nebivolol. Vasc Health Risk Manag. 2009;5(1):353–360. doi:10.2147/VHRM.S3056

133. Papaioannou T, Vlachopoulos C, Alexopoulos N, Dima I, Pietri P, Protogerou A et al. The effect of heart rate on wave reflections may be determined by the level of aortic stiffness: clinical and technical implications. Am J Hypertens. 2008;21(3):334–340. doi:10.1038/ajh.2007.52

134. Chow B, Rabkin S. The relationship between arterial stiffness and heart failure with preserved ejection fraction: a systemic meta-analysis. Heart Fail Rev. 2015;20(3):291–303. doi:10.1007/s10741-015-9471-1

135. Hashimoto J, Imai Y, Orourke M. Indices of pulse wave analysis are better predictors of left ventricular mass reduction than cuff pressure. Am J Hypertens. 2007;20(4):378–384. doi:10.1016/j.amjhyper.2006.09.019

136. Chirinos J, Phan T, Syed A, Hashmath Z, Oldland H, Koppula M et al. Late systolic myocardial loading is associated with left atrial dysfunction in hypertension. Circ Cardiovasc Imaging. 2017;10(6):e006023. doi:10.1161/CIRCIMAGING.116.006023

137. Sardana M, Syed A, Hashmath Z, Phan T, Koppula M, Kewan U et al. Beta-blocker use is associated with impaired left atrial function in hypertension. J Am Heart Assoc. 2017;6(2):e0055163.doi:10.1161/JAHA.116.005163

138. Nazário Leão R, Marques da Silva P, Marques Pocinho R,Alves M, Virella D, Palma dos Reis R. Determinants of left ventri-cular diastolic dysfunction in hypertensive patients. Hipertens RiesgoVasc. 2018;35(4):160–168. doi:10.1016/j.hipert.2017.12.002

139. Luchner A, Burnett J, Jougasaki M, Hense H, Riegger G, Schunkert H. Augmentation of the cardiac natriuretic peptides by beta-receptor antagonism: evidence from a population-based study. J Am Coll Cardiol. 1998;32(7):1839–1844. doi:10.1016/S0735–1097(98)00478-1

140. Dahlof B, Zanchetti A, Diez J, Nicholls M, Yu C, Barrios V et al. Effects of losartan and atenolol on left ventricular mass and neurohormonal profile in patients with essential hypertension and left ventricular hypertrophy. J Hypertens. 2002;20(9):1855–1864. doi:10.1097/00004872-200209000-00032

141. Linssen G, Rienstra M, Jaarsma T, Voors A, van Gelder I, Hillege H et al. Clinical and prognostic effects of atrial fibrillation in heart failure patients with reduced and preserved left ventricular ejection fraction. Eur J Heart Fail. 2011;13(10):1111–1120. doi:10.1093/eurjhf/hfr066

142. Edelmann F, Musial-Bright L, Gelbrich G, Trippel T, Radenovic S, Wachter R et al. Tolerability and feasibility of beta-blocker titration in HFpEF Versus HFrEF. JACC Hear Fail. 2016;4 (2):140–149. doi:10.1016/j.jchf.2015.10.008

143. Pandey A, Khera R, Park B, Haykowsky M, Borlaug B,Lewis G et al. Relative impairments in hemodynamic exercise reserve parameters in heart failure with preserved ejection fraction. JACC Hear Fail. 2018;6(2):117–126. doi:10.1016/j.jchf.2017.10.014

144. Brubaker P, Joo K, Stewart K, Fray B, Moore B, Kitzman D.Chronotropic incompetence and its contribution to exerciseintolerance in older heart failure patients. J Cardiopulm Rehabil. 2006;26(2):86–89. doi:10.1097/00008483-200603000-00007

145. Kitzman D. Conventional wisdom in heart failure treatment challenged again: does heart rate lowering worsen exercise intolerance in heart failure with preserved ejection fraction? Circulation. 2015;132(18):1687–1689. doi:10.1161/CIRCULA-TIONAHA.115.018954

146. Wilson J, Rayos G, Yeoh T, Gothard P, Bak K. Dissociation between exertional symptoms and circulatory function in patients with heart failure. Circulation. 1995;92(1):47–53. doi:10.1161/01.CIR.92.1.47

147. Phan T, Shivu G, Abozguia K, Davies C, Nassimizadeh M,Jimenez D et al. Impaired feart rate recovery and chronotropicincompetence in patients with heart failure with preserved ejectionfraction. Circ Hear Fail. 2010;3(1):29–34. doi:10.1161/CIRCHEART-FAILURE.109.877720


Рецензия

Для цитирования:


Кохан Е.В., Киякбаев Г.К., Кобалава Ж.Д. Повышенная частота сердечных сокращений у пациентов с артериальной гипертонией и ишемической болезнью сердца: маркер тяжести заболевания или корригируемый фактор риска при сохраненной фракции выброса левого желудочка. Артериальная гипертензия. 2019;25(4):389-406. https://doi.org/10.18705/1607-419X-2019-25-4-389-406

For citation:


Kokhan E.V., Kiyakbaev G.K., Kobalava Z.D. Elevated heart rate in hypertension and coronary artery disease: risk factor or risk marker in patients with preserved left ventricular ejection fraction. "Arterial’naya Gipertenziya" ("Arterial Hypertension"). 2019;25(4):389-406. (In Russ.) https://doi.org/10.18705/1607-419X-2019-25-4-389-406

Просмотров: 6721


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 1607-419X (Print)
ISSN 2411-8524 (Online)